Cougar Biotechnology to Present at Barclays Global Capital Healthcare Conference
05 March 2009 - 12:30AM
Business Wire
Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that
Alan H. Auerbach, Chief Executive Officer and President of Cougar,
will present at the Barclays Global Capital Healthcare Conference
on Wednesday, March 11, at 11:15 a.m. EDT at Loews Miami Beach
Hotel in Florida. Mr. Auerbach will provide a company overview and
update on the status of Cougar�s current clinical development
programs.
Interested investors may access a live audio webcast by visiting
the Investor Relations section of the Company�s Web site at
www.cougarbiotechnology.com. The presentation will be archived on
the Web site and available for 30 days.
About Cougar Biotechnology
Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology
company established to in-license and develop clinical stage drugs,
with a specific focus on the field of oncology. Cougar's oncology
portfolio includes CB7630, a targeted inhibitor of the 17-alpha
hydroxylase/c17,20 lyase enzyme, which is currently being studied
in a Phase III clinical trial in prostate cancer and a Phase I/II
trial in breast cancer; CB3304, an inhibitor of microtubule
dynamics, which is currently in a Phase I trial in multiple
myeloma; and CB1089, an analog of vitamin D, which has been
clinically tested in a number of solid tumor types.
Further information about Cougar can be
found at www.cougarbiotechnology.com.
Cougar Biotechnology (MM) (NASDAQ:CGRB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cougar Biotechnology (MM) (NASDAQ:CGRB)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Cougar Biotechnology (MM) (NASDAQ): 0 recent articles
More Cougar Biotechnology, Inc. News Articles